Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study

Härle, Peter; Letschert, Katrin; Wittig, B.; Mrowietz, Ulrich

doi:10.1159/000448029

Cited by 16 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many questionnaires available, including: Toronto Psoriatic Arthritis Screen II (ToPAS II), Psoriatic Arthritis Screening and Evaluation (PASE), Psoriasis Epidemiology Screening Tool (PEST), and Early Arthritis for Psoriatic Patients (EARP). 24,25 Sensitivities and specificities of questionnaires are well documented, 24,25 and studies comparing the effectiveness of questionnaire use to current standard of care at reducing delay in psoriatic arthritis diagnosis were identified as high priority.…”

Section: Discussionmentioning

confidence: 99%

“…23 Arthritis for Psoriatic Patients (EARP). 24,25 Sensitivities and specificities of questionnaires are well documented, 24,25 and studies comparing the effectiveness of questionnaire use to current standard of care at reducing delay in psoriatic arthritis diagnosis were identified as high priority.…”

Section: ) Are Outcomes Different For Psoriasis Patients Who Receivementioning

confidence: 99%

See 1 more Smart Citation

National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference

Afifi

Shankle

Armstrong

et al. 2017

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

The National Psoriasis Foundation (NPF) is developing an agenda for patient-centered research to help patients and their caregivers make more informed health care decisions by engaging psoriasis patients in prioritizing comparative effectiveness research (CER) topics. The NPF has created a novel patient-centered research platform known as Citizen Pscientist (CP), allowing patients with psoriasis and psoriatic arthritis to register and contribute their health data. The CP Governance Council administered an online 23-question CER survey to the CP community and held a structured meeting on December 3, 2016, with patients and researchers to review CER survey results and discuss patient-centered research priorities. Of the 2,945 patients surveyed, 792 patients responded. Three CER topics were deemed to be of high priority for the research agenda: 1) Treat-to-target therapy for psoriasis, 2) Psoriatic arthritis screening questionnaires for early detection and treatment of psoriatic arthritis, and 3) Comparative effectiveness of home-based phototherapy for psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: ) Are Outcomes Different For Psoriasis Patients Who Receivementioning

confidence: 99%

National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference

Afifi

Shankle

Armstrong

et al. 2017

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

show abstract

“…The currently available screening tools for PsA have been validated in various clinical settings; these tools include the Early Arthritis for Psoriatic Patients (EARP), German PsO Arthritis Diagnostic questionnaire, PsO Assessment Questionnaire (PAQ), Psoriatic Arthritis Screening and Evaluation (PASE), PsO and Arthritis Screening Questionnaire (PASQ), Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS) and ToPAS 2 . For this analysis, the validated PEST questionnaire was selected because it is an effective tool that can be used in clinical practice, is easy to use (just five questions) and is available in the Corrona PsO Registry.…”

Section: Introductionmentioning

confidence: 99%

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry

Mease

Palmer

Hur

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool ( PEST ) is a five‐item questionnaire developed to help identify PsA at an early stage. Objectives To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores. Methods This study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient‐reported outcomes were compared in Corrona PsO Registry patients with PEST scores ≥3 and <3 using t ‐tests for continuous variables and chi‐squared tests for categorical variables; scores ≥3 may indicate PsA. Results Of 1516 patients with PsO, 904 did not have dermatologist‐reported PsA; 112 of these 904 patients (12.4%) scored ≥3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores <3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment. Conclusions Improved PsA screening is needed in patients with PsO because the validated PEST identified over one‐tenth of registry patients who were not noted to have PsA as having scores ≥3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health‐related quality of life and worse activity impairment.

show abstract

“…With the use of ultrasound, magnetic resonance, and scintigraphy, the rate of diagnosis of inflammatory joint manifestations increased to 79.6%. Considering the limitations in the availability of complementary methods, in 2016 the same authors presented a study in which they showed the usefulness of this questionnaire under conditions of usual clinical practice [16]. They recruited 1,512 patients with psoriasis in ambulatory dermatology centers (universities/general hospitals and doctor’s offices) throughout Germany, 52.9% (800/1,512 patients) of whom had ≥4 points in the GEPARD questionnaire.…”

Section: Introductionmentioning

confidence: 99%

“…They recruited 1,512 patients with psoriasis in ambulatory dermatology centers (universities/general hospitals and doctor’s offices) throughout Germany, 52.9% (800/1,512 patients) of whom had ≥4 points in the GEPARD questionnaire. The prevalence of PsA according to the CASPAR classification criteria was 33.8% (175/517 patients) of those patients with a positive GEPARD questionnaire [16]. Considering the importance of having simple tools that allow the detection of PsA in patients with psoriasis, we have developed a translation of the GEPARD questionnaire and evaluated its performance in Argentinian patients.…”

Section: Introductionmentioning

confidence: 99%

Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis

Martire

Bosch

Scarafia³

et al. 2019

Dermatology

View full text Add to dashboard Cite

Background/Objective: Psoriatic arthritis (PsA) is preceded by psoriasis in approximately 80% of cases. Dermatologists are pivotal for early detection. It is important to have simple tools that allow the detection of PsA in patients with skin psoriasis. The aim of our study was to evaluate the performance of an adapted version of the GEPARD Questionnaire in Spanish in Argentinian patients with psoriasis. Methods: This is a cross-sectional study. A new Spanish (Argentinian) (GEPARDa) translated version of the original questionnaire (German) was developed and then tested as a diagnostic tool in patients with psoriasis, PsA, osteoarthritis associated to psoriasis, and osteoarthritis, all evaluated by rheumatologists who used the CASPAR criteria. Results: Eighty-three patients were included (55 [66.3%] women with a mean age of 50.7 years [SD 6.3]). Forty-four patients had PsA (29 [34.9%] patients had previous diagnosis of PsA, and 15 [18%] were newly diagnosed after referral by their dermatologists), and 39 patients were without PsA (18 [21.6%] patients had psoriasis without articular involvement, 6 [7.22%] had psoriasis associated with osteoarthritis, and 15 [18%] had osteoarthritis). An area under the curve of 0.9554 (SD 0.01; 95% CI 0.91–0.99) was calculated considering the CASPAR criteria as the gold standard. With a cutoff of ≥6 the questionnaire showed a sensitivity of 88.64%, a specificity of 89.74%, a positive likelihood ratio of 8.6, and a negative likelihood ratio of 0.12. Conclusions: The GEPARDa version has proven to be a diagnostic tool with excellent performance so that it can be considered a valid tool for the detection of PsA in Argentinian patients.

show abstract

Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study

Cited by 16 publications

References 26 publications

National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference

National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry

Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis

Contact Info

Product

Resources

About